Altimmune Historical Balance Sheet
ALT Stock | USD 7.38 0.11 1.47% |
Trend analysis of Altimmune balance sheet accounts such as Other Current Liab of 17.1 M, Total Current Liabilities of 21.2 M or Total Stockholder Equity of 203.8 M provides information on Altimmune's total assets, liabilities, and equity, which is the actual value of Altimmune to its prevalent stockholders. By breaking down trends over time using Altimmune balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Altimmune latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Altimmune is a good buy for the upcoming year.
Altimmune Inventory |
|
Altimmune |
About Altimmune Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Altimmune at a specified time, usually calculated after every quarter, six months, or one year. Altimmune Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Altimmune and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Altimmune currently owns. An asset can also be divided into two categories, current and non-current.
Altimmune Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Altimmune assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Altimmune books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Altimmune balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Altimmune are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Accounts Payable
An accounting item on the balance sheet that represents Altimmune obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Altimmune are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most accounts from Altimmune's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Altimmune current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altimmune. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Altimmune Stock please use our How to Invest in Altimmune guide.At this time, Altimmune's Other Stockholder Equity is comparatively stable compared to the past year. Total Liabilities is likely to gain to about 27.3 M in 2024, whereas Accounts Payable is likely to drop slightly above 1.5 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 6.1M | 11.8M | 9.6M | 17.1M | Total Assets | 218.9M | 206.9M | 210.6M | 221.2M |
Altimmune balance sheet Correlations
Click cells to compare fundamentals
Altimmune Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Altimmune balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Liab | 3.6M | 11.0M | 6.1M | 11.8M | 9.6M | 17.1M | |
Total Current Liabilities | 3.9M | 12.0M | 18.3M | 17.1M | 12.1M | 21.2M | |
Total Stockholder Equity | 45.5M | 225.9M | 199.1M | 185.3M | 194.1M | 203.8M | |
Net Debt | (7.2M) | (114.1M) | (188.8M) | (110.0M) | (134.5M) | (127.8M) | |
Retained Earnings | (137.4M) | (186.4M) | (293.2M) | (377.9M) | (466.3M) | (443.0M) | |
Accounts Payable | 18.2K | 612.3K | 2.0M | 4.8M | 2.1M | 1.5M | |
Cash | 9.0M | 115.9M | 190.3M | 111.1M | 135.2M | 141.9M | |
Cash And Short Term Investments | 37.2M | 215.9M | 190.3M | 184.9M | 197.9M | 207.7M | |
Common Stock Total Equity | 876.0 | 1.5K | 3.7K | 4.1K | 4.7K | 3.9K | |
Common Stock Shares Outstanding | 13.1M | 25.6M | 41.3M | 46.9M | 53.2M | 55.9M | |
Liabilities And Stockholders Equity | 54.1M | 245.1M | 218.9M | 206.9M | 210.6M | 221.2M | |
Other Current Assets | 504.4M | 2.0B | 13.4B | 5.4M | 6.8M | 6.5M | |
Other Stockholder Equity | 187.9M | 417.3M | 497.3M | 568.4M | 665.4M | 698.7M | |
Total Liab | 8.5M | 19.2M | 19.7M | 21.6M | 16.5M | 27.3M | |
Total Current Assets | 39.4M | 230.3M | 204.1M | 192.8M | 209.5M | 220.0M | |
Common Stock | 1.5K | 3.7K | 4.1K | 5K | 7K | 4.2K | |
Other Assets | 128.5K | 977.2K | 73.8K | 19K | 1.0 | 0.95 | |
Non Current Liabilities Total | 4.6M | 7.2M | 1.5M | 4.6M | 4.4M | 4.7M | |
Short Term Debt | 259.4K | 356.7K | 411.5K | 452K | 496K | 471.2K | |
Short Long Term Debt Total | 1.7M | 1.8M | 1.5M | 1.1M | 671K | 637.5K | |
Property Plant And Equipment Net | 1.8M | 2.0M | 1.4M | 1.1M | 1.0M | 1.5M | |
Non Current Assets Total | 14.7M | 14.9M | 14.7M | 14.1M | 1.1M | 1.1M | |
Non Currrent Assets Other | 128.5K | 73.4K | 872.0K | 615K | 100.0K | 95.0K | |
Net Receivables | 1.7M | 12.4M | 5.8M | 2.5M | 4.9M | 5.0M | |
Property Plant And Equipment Gross | 1.8M | 2.0M | 1.4M | 2.6M | 2.6M | 1.6M | |
Accumulated Other Comprehensive Income | (5.0M) | (5.0M) | (5.0M) | (5.2M) | (5.0M) | (4.8M) | |
Intangible Assets | 12.7M | 12.8M | 12.4M | 12.4M | 14.3M | 11.8M | |
Net Tangible Assets | 32.8M | 213.1M | 186.7M | 172.9M | 198.8M | 208.7M | |
Long Term Debt | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 1.5M | |
Retained Earnings Total Equity | (116.9M) | (137.4M) | (186.4M) | (293.2M) | (337.1M) | (354.0M) | |
Capital Surpluse | 170.2M | 187.9M | 417.3M | 497.3M | 571.9M | 600.5M | |
Property Plant Equipment | 1.1M | 1.1M | 1.4M | 1.7M | 1.9M | 2.0M | |
Long Term Debt Total | 1.9M | 1.9M | 1.8M | 1.5M | 1.7M | 2.0M | |
Non Current Liabilities Other | 2.8M | 5.4M | 1.5M | 3.9M | 4.2M | 4.4M | |
Other Liab | 3.1M | 7.2M | 330.5K | 3.9M | 4.5M | 3.3M |
Pair Trading with Altimmune
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altimmune will appreciate offsetting losses from the drop in the long position's value.Moving together with Altimmune Stock
0.76 | VANI | Vivani Medical | PairCorr |
0.82 | DRTS | Alpha Tau Medical | PairCorr |
0.78 | CRL | Charles River Labora | PairCorr |
0.75 | ICU | LMF Acquisition Oppo | PairCorr |
Moving against Altimmune Stock
The ability to find closely correlated positions to Altimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altimmune to buy it.
The correlation of Altimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.